Special Emphasis Panel: Therapeutic Development for Neurological Disorders – NPB (56)
The Therapeutic Development for Neurological Disorders study section reviews applications focused on early phase of drug discovery for different neurological diseases including but not limited to Alzheimer’s disease related dementias (ADRD), neurodegenerative movement disorders, epilepsy, brain injuries, neuroautoimmune, psychiatric, and neurodevelopmental disorders. Studies reviewed in this panel focus on early stages of therapeutic development. Studies may use in animal models, cell cultures, organoids, and other in vitro systems.
Review Dates
A roster for the panel will be posted here, at least 30 days prior to the review meeting
Topics
- Discovery of novel agents for neurological disorders including small molecules, biologics (vaccines, growth factors, immune modulators, monoclonal antibodies exomes), natural products, prodrugs, repurposed drugs, gene and nucleic acid therapies, cell-based modalities, and combination regimens.
- Biological and mechanistic characterization of new agents interaction with molecular targets and pathways, including target druggability, mechanism of action, structural characterization of drug complexes, and confirmation of target engagement.
- Development of assays to support therapeutic discovery and biomarker detection.
- Design and development of new molecular entities/ vehicles for targeted delivery of neurological therapeutics (eg, polymers, micelles and nanoparticles)
Development of models and platforms to test drug efficacy, including cellular, organoids, and animals.
